Change Bisphosphonate Labeling, Agency Panel Recommends
A joint FDA advisory committee voted 17–6 Sept. 9 to recommend labeling changes clarifying the recommended length of bisphosphonate use for osteoporosis patients.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.